Photo taken from Deniz Can Guven/X
Jun 24, 2024, 03:22
Deniz Can Guven: The OS benefits of cancer drugs approved by surrogate endpoints
Deniz Can Guven, The Editorial Board Member in BMC Cancer, shared on X:
“Out in The Lancet Oncology in OA. The OS benefits of cancer drugs approved by surrogate endpoints.
- 38 indications with OS data after approval
- Significant OS benefit in only 32% of the indications
- Late availability of (>3 years) non-significant OS results
The value of surrogate endpoints in approvals. A double-edged sword.”
Source: Deniz Can Guven/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 19:25
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08